Eyenovia (EYEN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.04 (-23.76%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Eyenovia (EYEN)
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Key Insights

Critical company metrics and information

  • Share Price

    $0.12

  • Market Cap

    $13.38 Million

  • Total Outstanding Shares

    111.43 Million Shares

  • Total Employees

    57

  • Dividend

    No dividend

  • IPO Date

    January 25, 2018

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Phone Number

    813-766-9539

  • Address

    295 madison avenue,, New york, NY, 10017

  • Homepage

    https://www.eyenovia.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-30.33 Million
Net Cash Flow From Investing Activities$-306,707.00
Net Cash Flow From Financing Activities$17.12 Million
Net Cash Flow$-13.51 Million
Net Cash Flow From Investing Activities, Continuing$-306,707.00
Net Cash Flow From Operating Activities$-30.33 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Revenues$31,832.00
Income/Loss From Continuing Operations Before Tax$-21.97 Million
Diluted Earnings Per Share$-0.69
Net Income/Loss Available To Common Stockholders, Basic$-37.83 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$3.29 Million
Other Non-current Assets$2.18 Million
Equity Attributable To Noncontrolling Interest$0.00
Wages$1.66 Million
Non-current Prepaid Expenses$46,520.00
Liabilities And Equity$22.80 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.